The main finding of our study was that hypomethylation of BIN1 promoter might increase the risk of preclinical AD and be associated with more severe pathological changes of CSF AD core biomarkers in elderly adults without objective cognitive impairment. Here, BIN1 is linked to Cognitive impairment.